Aligos Therapeutics, Inc.

NasdaqCM:ALGS Stock Report

Market Cap: US$40.0m

Aligos Therapeutics Future Growth

Future criteria checks 5/6

Aligos Therapeutics is forecast to grow earnings and revenue by 51.9% and 58.1% per annum respectively. EPS is expected to grow by 58.9% per annum. Return on equity is forecast to be -94.9% in 3 years.

Key information

51.9%

Earnings growth rate

58.93%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate58.1%
Future return on equity-94.91%
Analyst coverage

Low

Last updated12 May 2026

Recent future growth updates

Recent updates

Analysis Article • Dec 09

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 25

Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 11

Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Dec 11

Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks

Summary Aligos Therapeutics focuses on ALG-000184 for CHB and ALG-055009 for MASH, targeting large, underserved markets with growing TAMs. ALG-000184’s Phase 1 data show strong antiviral activity and a favorable safety profile. Phase 2 trials are set to begin in Q1 2025. ALG-055009 achieved 46.2% liver fat reduction in Phase 2a trials for MASH, positioning it as a promising but competitively challenged therapeutic candidate. Financial risks remain significant, with a 3.7-quarter cash runway and a $400M mixed-shelf offering signaling potential dilution for shareholders. Despite its promising pipeline with ALG-000184 and ALG-055009, cash runway issues and potential dilution risks justify a neutral "Hold" rating. Read the full article on Seeking Alpha
Analysis Article • Nov 27

Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 31

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Those holding Aligos Therapeutics, Inc. ( NASDAQ:ALGS ) shares would be relieved that the share price has rebounded 49...
Analysis Article • Jul 16

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 24

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics, Inc. ( NASDAQ:ALGS ) shares have had a horrible month, losing 27% after a relatively good period...
Analysis Article • Apr 09

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Aligos Therapeutics, Inc. ( NASDAQ:ALGS ) shares have been powering on, with a gain of...
Analysis Article • Feb 23

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

You may think that with a price-to-sales (or "P/S") ratio of 3.8x Aligos Therapeutics, Inc. ( NASDAQ:ALGS ) is...
Analysis Article • Oct 24

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 17

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 11

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jul 25

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Aligos Therapeutics (NASDAQ:ALGS) said it had begun enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B subjects in the ongoing Phase 1b study of ALG-000184-201. "With the initiation of this 12-week cohort at the 100 mg dose level, we can now explore whether longer-term dosing continues to be well tolerated and if greater suppression of important viral parameters, including HBV DNA and RNA, in HBeAg-positive subjects can be achieved," said Lawrence Blatt, CEO at Aligos.
Analysis Article • Jul 11

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 02

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:ALGS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028239-14-100-1221
12/31/20273-120-106-1173
12/31/202612-98-93-853
3/31/20265-90-85-85N/A
12/31/20252-24-83-83N/A
9/30/20253-86-80-79N/A
6/30/20253-74-75-75N/A
3/31/20253-53-79-79N/A
12/31/20244-131-81-81N/A
9/30/20246-77-85-85N/A
6/30/20248-76-85-85N/A
3/31/202414-100-79-79N/A
12/31/202316-88-79-79N/A
9/30/202316-82-73-73N/A
6/30/202317-82-70-70N/A
3/31/202314-83-82-81N/A
12/31/202214-96-80-79N/A
9/30/202211-112-101-100N/A
6/30/20228-126-110-108N/A
3/31/20226-136-107-106N/A
12/31/20214-128-117-116N/A
9/30/20214-125-98-98N/A
6/30/20212-125-90-89N/A
3/31/20211-116-85-84N/A
12/31/2020N/A-109-76-74N/A
9/30/2020N/A-92-72-70N/A
6/30/2020N/A-73-69-66N/A
3/31/2020N/A-62-61-58N/A
12/31/2019N/A-52N/A-47N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALGS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: ALGS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALGS is expected to become profitable in the next 3 years.

Revenue vs Market: ALGS's revenue (58.1% per year) is forecast to grow faster than the US market (11.6% per year).

High Growth Revenue: ALGS's revenue (58.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALGS is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/13 19:03
End of Day Share Price 2026/05/13 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aligos Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Antonio ArceH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.
Yuxi DongJefferies LLC